Skip to main content
. 2017 Feb 3;6(3):819–829. doi: 10.1002/sctm.16-0335

Figure 1.

Figure 1

Expression of CD44 and hairy enhancer of split‐1 (Hes1) in human gastric cancer (GC) cell lines and tissues. (A): Table showing the % of CD44 expression from a panel of five human GC cell lines. (B): Immunoblot analysis of human GC cell lines for same targets with highest expression in MKN45 cells. (C): Immunoblot analysis of CD44, Hes1, and wnt 5a/b expression in human tissues (Normal‐N, Gastritis‐G, Cancer‐GC) with significant increase in the tumor samples. β‐actin was used as a loading control. (D): Activation of Notch pathway in CD44+ cancer stem cells was assesed by FACS showing a significant increase in Hes1 expressing cells compared to CD44− cells. (E): Bar graphs representing the different intensities of CD44 and Hes1 expression in a panel of 269 human GC tisssues. 80% of the samples showed positive CD44 and 89% positive HES1 expression. *GC tumor tissues showing both moderate and strong staining for Hes1 or CD44 were considered to be positive whereas tumor tissues showing both weak and negative staining were considered to be negative. (F): Kaplan‐Meier overall survival curve for GC patients stratified by Hes1 and CD44 expression, showing a significant diference. **p < .005. Abbreviation: Hes1, hairy enhancer of split‐1.